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INTRODUCTION 
Systemic sclerosis is a generalised disorder of connective tissue(1) 
characterized clinically by thickening and fibrosis of skin and by distinctive form of  
involvement of internal organs, notably the heart, lungs, kidneys and gastrointestinal 
tract(2). Morbidity and mortality are substantial and are directly related to the extent 
and severity of visceral involvement (1). Scleroderma or systemic sclerosis is 
characterized by fibrosis and micro vascular occlusion. These two processes are seen 
in all involved organs of patients with systemic sclerosis. 
The etiology of systemic sclerosis remains elusive despite significant advances 
in the understanding of the pathogenic mechanisms of the disease since its initial 
description in the medical literature almost 250 years ago. Systemic sclerosis (SSc) 
can be conceptualized as tripartite disease in which dysfunction of the immune 
system, endothelium, and fibroblasts give rise to a heterogeneous  phenotype that is 
marked by prominent fibrosis(3). 
Autoimmunity is manifested by the elaboration of circulating disease specific 
auto antibodies (4).  Fibroblast dysfunction is manifested as fibrosis of skin and 
internal organs as the result of increased synthesis and deposition of extra cellular 
matrix (ECM) proteins (5, 6).  Raynaud’s phenomenon, capillary dropout, endothelial 
injury/apoptosis, and abnormalities in vascular tone are manifestations of endothelial 
cell dysfunction. 
Genetic factors may play a role in the dysregulation of these components by 
affecting host susceptibility to disease or modifying clinical presentation and organ 
damage. Available data are consistent with the paradigm that the phenotype identified 
as SSc is the end result of a complex interaction of genetic factors and unknown 
environmental influences. 
  The pathologic hallmark of systemic sclerosis is an excessive accumulation of 
extra cellular matrix (ECM) in the dermis, which leads to taut skin. Thinning of 
papillary dermis with deposits of fibrinonectin, glycosaminoglycans and tenacin play 
a crucial role. In the early stages of systemic sclerosis, an infiltration of mononuclear 
inflammatory cells, predominantly T cells (8), surrounding the dermal blood vessels is 
concentrated at the border between the reticular dermis and subcutaneous fat. There is 
intimal proliferation with luminal narrowing at the arterial and arteriolar levels. 
Capillary loss can be seen in vivo in the skin by wide field nail fold capillaroscopy. 
(9). 
One of the vascular hallmarks of systemic sclerosis, of either the limited 
(subcutaneous Calcinosis, Raynaud’s phenomenon, Esophageal dysmotility, 
Sclerodactyly, Telengiectasia CREST syndrome) or diffuse form of the disease, is 
telengiectasia over the face, hands and anterior chest. Fibrotic and vascular lesions 
occur in the lungs of patients with systemic sclerosis. Marked   intimal proliferation 
with narrowing of the lumen is accompanied by medial thickening resulting in 
pulmonary hypertension, and eventual right heart failure. The initial stage of the 
pulmonary fibrotic lesion is inflammation within the alveolar air spaces (10) 
Scleroderma is a generic term used to describe both disease restricted to the 
skin(localized scleroderma) and disease with internal organ involvement.(systemic 
sclerosis).There are two main categories of systemic sclerosis, limited cutaneous 
systemic sclerosis (lSSc) and diffuse systemic sclerosis(dSSc). Limited cutaneous 
systemic sclerosis is skin thickening confined to the extremities distal to the elboews 
and knees, without truncal involvement (facial involvement is permitted).Diffuse 
cutaneous systemic sclerosis is skin involvement that, at one time, includes the 
proximal extremities or the trunk.Scleroderma sine scleroderma describes about 5% 
of systemic sclerosis patients who have no skin involvement but do have 
characteristic gut or other internal organ damage. 
Limited cutaneous systemic sclerosis is more common than the diffuse version 
of the disease, but exact ratios are unknown because of a bias towards under-
diagnosis. Patients with the CREST syndrome of Calcinosis, Raynud’s phenomenon, 
Esophageal dysmotility, Sclerodactyly, and Telengiectasia are a subset of limited 
cutaneous patients. Other patients with lSSc (limited cutaneous systemic sclerosis)   
or dSSc (diffuse cutaneous systemic sclerosis) may have calcinosis, Raynaud’s 
phenomenon, esophageal dysmotility, or telengectasia and systemic sclerosis patients 
are not given the diagnosis of CREST just because they have one or more of these 
later manifestations. 
Limited cutaneous patients with anticentromere antibodies are at lower risk of 
developing interstitial lung disease than other patients, but are at high risk of 
pulmonary hypertension. Limited cutaneous patients are at less risk of developing 
heart involvement, renal crisis, and pseudo- obstruction. Patients with dSSc usually 
present progressive skin thickening, fatigue, anorexia, and weight loss. This subset of 
patients is more likely to develop interstitial lung disease and pulmonary 
hypertension.  
HEART: 
Pericardial and myocardial lesions can occur in systemic sclerosis. Fibrosis 
and occasional constriction can occur at pericardium. The myocardium shows intimal 
proliferation and luminal narrowing of the small vessels. Surrounding the damaged 
blood vessels is fibrosis replacing the myocardium. The early lesion is contraction 
band necrosis. The histologic evidence suggests the primary insult in the myocardium 
is ischemic and is the result of structural vascular disease and vasospasm. (11). 
Gastrointestinal tract, kidneys, musculoskeletal system can get involved in the 
pathogenetic process showing variable involvement (12) 
Evidence from multiple sources indicates that SSc does not occur randomly at 
population. Incidence at United States is 20 per million per year. The incidence tends 
to remain stable in some areas whereas incidence and prevalence seems to vary in 
different areas. Survival has improved over past few decades. Mean survival is 12 
years from diagnosis (13). Renal disease accounts for early mortality, but pulmonary 
disease has emerged as a major cause of death and is associated with a poorer 
prognosis. Women are affected more frequently than men but the exact cause of this 
is not known. Some studies predict that the number of pregnancies may influence later 
disease expression (14). 
Racial factors play a role in disease susceptibility and expression. Age specific 
incidence rates are higher in black women than in white; the greatest difference 
occurs in the young to middle adult age group (15) (less than 54 years of age). 
Diffuse occur more commonly in blacks than in whites. Age at onset of diffuse 
is younger than the onset of limited disease. It is likely that there is a strong interplay 
among genetic factors, hormonal or reproductive-related events, and an external 
trigger that must interact to result in clinical disease. 
Heine in 1926 and Weiss and colleagues in 1943 were the first to report 
cardiac involvement in SSc. Clinical presentation of cardiac involvement include 
dyspnea, features of pulmonary hypertension, palpitation, CCF, aypical chest pain, 
typical angina occasionally, and cardiomyopthy. Cardiac involvement is often 
clinically occult and the prevalence of cardiac disease varies depending on the 
methods used to define the cardiac involvement. Myocardial fibrosis is the hallmark 
of cardiac involvement. SSc cardiac fibrosis may involve the immediate 
subendocardial layer, typically spared in atherosclerosis. Systolic and diastolic 
dysfunction may occur. Conduction disturbances and pericardial involvement may 
occur. Cardiac involvement in limited and diffuse disease vary. 
INTERSTITIAL LUNG DISEASE IN SYSTEMIC SCLEROSIS 
Lung involvement in systemic sclerosis is almost universal and now accounts 
for significant morbidity. Both interstitial fibrosis and pulmonary arterial vascular 
disease are present in the lungs of patients with scleroderma but often one pathologic 
process will be the dominant cause of clinical problems. Pulmonary interstitial 
fibrosis is more likely to be severe in patients with diffuse disease while pulmonary 
vascular disease and pulmonary hypertension can be the dominant problem of the 
lung in patients with CREST syndrome. 
Most patients have some degree of both processes and all patients with 
interstitial lung disease and pulmonary hypertension should be evaluated thoroughly. 
80% of patients will have abnormal PFT (Pulmonary Function Tests) measured by 
specific and sensitive testing. Yet, the majority of the lung disease will be clinically 
silent until advanced pulmonary fibrosis or moderate to severe pulmonary arterial 
hypertension is present. Dyspnea on exertion is the initial complaint and dry cough a 
late feature of ILD (Interstitial lung disease). Velcro-like crackles at lung bases are 
characteristic. Chest radiograph is relatively insensitive but if abnormal, the fibrosis 
appears as bilateral reticulonodular changes in the lower lobes of the lung 
parenchyma. 
PFT shows a restrictive type of ventilatory defect. The most common 
abnormality is reduced diffusion capacity or a reduction in lung volumes (forced vital 
capacity) typical of a restrictive defect with associated reduction in gas exchange. 
HRCT (High resolution computed tomography) is very sensitive for detecting changes 
in lung parenchyma. Findings of ground glass opacification of the lung bases on 
HRCT correspond with active alveolitis and progressive restrictive lung disease. 
Bronchoalveolar lavage(BAL) is used to detect inflammation and active alveolitis. 
BAL demonstrates an increased total number of cells with an increase in neutrophils, 
eosinophils or CD8+ T cells. Evidence of active alveolitis by either BAL or HRCT 
predicts progressive lung disease. 
Pulmonary arterial vascular disease with associated pulmonary hypertension is 
one of the difficult clinical situations in systemic sclerosis. The pulmonary vascular 
process can be indolent and remain clinically undetectable until severe irreversible 
pulmonary hypertension and right sided cardiac failure develop. The natural course of 
the lung disease is variable. The majority will have an early but modest decline in 
function and then follow a stable course or improve. One third will have a more 
severe progressive decline in lung function that continues for 4-5 years and then 
stabilize. 
 
 
 
 
 
 
REVIEW OF LITERATURE 
Like other connective tissue disorders, systemic sclerosis is also predominant 
in females, 3-5:1 most commonly, but as high as 14:1 in some populations. The 
female: male ratio is greatest in childbearing years. 
Steen VD et al described age of onset of scleroderma is most commonly in the 
range of 30-50 years. (38). The mean age of onset in white men and women are 44 
and 42 years. This is similar in patients in both subsets of scleroderma, limited 
cutaneous and diffuse cutaneous, although patients with limited scleroderma not 
usually diagnosed until 5-10 years later. 
Walker UA et al in their study of clinical risk assessment for organ 
manifestations in systemic sclerosis and in order to better understand the vascular, 
immunological and fibrotic processes of SSc and to guide its treatment studied a total 
of 3656 patients (1349 with dcSSc and 2101 with lcSSc), enrolled in 102 centers and 
30 countries and concluded that 1330 individuals had auto antibodies against Scl70 
and 1106 against anticentromere antibodies and  87% of patients were female. On 
multivariate analysis, scleroderma subsets (dcSSc vs lcSSc), antibody status and age 
at onset of Raynaud's phenomenon, but not gender were independently associated 
with the prevalence of organ manifestations. 
The Eustar Meds data base facilitates the analysis of clinical patterns in SSc 
and contributes to the standardized assessment and monitoring of SSc internationally 
(17). 
Sharma et al in their study have reported the clinical and immunological 
profile of patients from North India between 2001 and 2004 .84 females and 16 males 
with systemic sclerosis with mean age of 32 were reported. The reported profile 
included Raynaud’s phenomenon in 92.9%, ANA positivity in 89.1%, abnormal chest 
X ray in 65.3% and reduced pulmonary function test in 85.8% and these features in 
North Indian population was similar to that of other ethnic groups (18).  
Krishnamurthy et al have reported a study of 78 patients and they have 
reported a female preponderance(3.5:1) with a peak age of occurrence in the 4th 
decade(32%), Raynaud’s phenomenon in 28%,ANA positivity in 56.8%,abnormal 
echocardiography in31% and restrictive type of pulmonary function in 55%(19).  
SCLERODERMA CLASSIFICATION AND SUBSETS: 
The epidemiology and natural history of scleroderma revolve around the two 
major scleroderma subsets. The American College of Rheumatology criteria for the 
classification (not diagnosis) of scleroderma was established in 1980. The major 
criterion is skin thickening proximal to the metacarpophalangeal joints; minor criteria 
(two of the minor criteria are required) include sclerodactyly, digital pitting scars or 
loss of digital finger pad substance and bibasilar pulmonary fibrosis. Patients had to 
have had symptoms for less than 2 years. This resulted in a smaller number of patients 
with limited scleroderma, because the early diagnosis of limited scleroderma is 
infrequent. 
Patients with limited diseases have skin thickening of distal extremities and 
face. They may not have all the features of CREST syndrome, although many of them 
do. The extent of the skin thickening and the pace of the disease differentiate limited 
and diffuse skin disease. The disease onset in patients with limited scleroderma is 
usually with Raynaud’s  phenomenon, which is alone present for years before any 
other manifestations occur; at some time, possibly 5 -10 years later, they develop 
puffy, swollen fingers, digital tip ulcers, telengiectasis or esophageal symptoms 
enabling  a diagnosis of limited scleroderma. In contrast, patients with diffuse 
cutaneous disease have a much more acute onset of symptoms including Raynaud’s 
phenomenon, swollen  hands and legs, carpal tunnel syndrome, arthralgia /arthritis 
and fatigue, all  occurring in a short span of time. 
Diagnosis of diffuse scleroderma occurs usually after skin thickening becomes 
evident, 1 -12 months after the onset of other symptoms. The pattern of organ 
involvement is also different. Interstitial fibrosis occurs in both forms and is related to 
the anti Scl-70 antibody. Isolated pulmonary hypertension occurs more prominently in 
limited scleroderma, whereas renal disease and cardiac disease occur predominantly 
in diffuse scleroderma. 
Classically, the anticentromere (ACA) antibody is seen in limited scleroderma 
with greater frequency in women. It is seen in 30 to90% patients with limited 
scleroderma (20). Antitopoisomerase-I or Scl-70 is the other scleroderma antibody for 
which commercial tests are available.  However, about 25% of these patients do not 
have extensive skin, heart or kidney problems and their disease follows a course 
similar to that of limited scleroderma. In addition with the association with diffuse 
cutaneous disease, Scl-70 is associated with more pulmonary interstitial fibrosis and 
more vascular problems. 
However these patients are protected from the isolated vasculopathy type of 
pulmonary hypertension. Cardiac disease and renal crisis complicate clinical picture 
when Scl-70 is present. Anti-RNA polymerase III is another commonly seen 
scleroderma specific antibody, which is found almost exclusively in diffuse 
scleroderma (28%), but assays are commercially not yet available. 
A nucleolar pattern of antinuclear antibodies is very specific to scleroderma, 
and three different specific antibodies have been identified. One of them, anti U3 
RNP or antifibrillarin, is the most frequent antibody seen in African Americans. It is 
associated with diffuse disease, pulmonary fibrosis, and isolated pulmonary 
hypertension. The other nucleolar antibodies, anti Th/To and anti Pm/Scl, are more 
frequent in patients with limited scleroderma. Pulmonary hypertension and myositis 
are common in patients with these antibodies. The most recently described 
scleroderma specific autoantibody is an auto antibody to fibrillin-1, a major structural 
protein of connective tissue micro fibrils(21). 
The etiology of these auto antibodies is not very clear. They have not been 
shown to be pathogenic, but clearly appear to be markers of specific forms of the 
disease. They are almost seen at the time of physician evaluation and rarely disappear. 
They could be   present for years before the onset of symptoms. One possibility is that 
they represent body’s reaction to different triggers of the disease, perhaps 
environmental or occupational. In general, countries that have a large number of 
patients with limited scleroderma have a high frequency of anticentromere antibody. 
This strongly suggests that the anti-bodies are directly related to the subset of patients, 
and thus may play a larger part in the pathogenesis than do other factors. 
Genetic factors: 
Genetic factors appear to have a pathogenic role in scleroderma. 
Chromosomal breakage have been implicated but not conclusively proven. More 
recent data have been based on variable number tandem repeats, a technique that can 
show chromosomal abnormalities (22). Other pathogenic theory is that of 
microchimerism, in which the hypothesis is that the patients have a reaction to fetal 
cells from an early pregnancy or from their parents (in order to account for the 
occurrence in males and nulliparous females) (23) after which the patients develop a 
graft versus host reaction that results in scleroderma. Although the supporting data are 
reasonable, no correlation between scleroderma subtypes and auto antibodies is noted. 
But this is not fully tenable due to primary differences between graft Vs host disease 
and scleroderma. 
Major histocompatability complex alleles did not have a major association 
with systemic sclerosis. A 1987 study showed that C4A-null alleles had the greatest 
association. DQA2, B8, DR3, and DQ2 have all been implicated. Some authors opine 
that DQ7 and DQ5 are more common (24). Limited types are correlated with HLA 
DR1 and diffuse types with DR5. Having a first degree relative with systemic 
sclerosis is the strongest risk factor for the disease 
OCCUPATIONAL AND ENVIRONMENTAL RISK FACTORS: 
Silica exposure, vibration, polyvinyl chloride and variety of other organic 
solvents tend to produce a scleroderma like illness. Drugs have been implicated with 
the development of scleoderma including appetite suppressants, 1-5 
hydroxytryptophan, bleomycin, pentazocine and cocaine. Despite strong suspicion it 
has not been able to implicate silicon breast implants with systemic sclerosis. 
CARDIAC INVOLVEMENT IN SYSTEMIC SCLEROSIS 
In the study of Walker UA et al,  palpitations, dyspnea on exertion, and chest 
discomfort are described  as  common features(17).They have reported palpitations in 
34%,dyspnea in 47% and chest discomfort in 31% of their patents. Follansbee et al 
study revealed pericarditis, congestive cardiac failure, pulmonary hypertension and 
arrhythmias are the main categories of cardiac disease seen in both subtypes of 
systemic sclerosis (25).  Dyspnea on exertion is more often due to scleroderma lung 
disease than due to cardiac involvement until late in the course of the disease. 
 Follansbee et al noted clinical evidence of cardiac disease in 20 to 25% of 
patients with systemic sclerosis(26). Palpitation, atypical chest pain, or syncope may 
be due to arrhythmias or pericardial disease. Ischemic chest pain and myocardial 
infarct are uncommon. 
Steen VD et al noted that the thallium perfusion defects reflecting vascular 
disease of endomyocardial vessels (not larger coronary vessels) are seen both at rest 
and during exertion. Cold provocation of Raynaud’s phenomenon can temporarily 
increase the nature of thallium perfusion defects and induces abnormalities of 
ventricular wall motion indicating that reversible vasospasm of the myocardial 
circulation occurs in scleroderma. Patchy myocardial fibrosis can occur due to 
ischemic reperfusion   events in the heart musculature causing contraction band 
necrosis of cardiac muscle. Left and right ventricular dysfunction is common in 
scleroderma and diastolic dysfunction can occur independent of systolic dysfunction. 
Steen and Follansbee et al suggested abnormal left ventricular compliance 
and pulmonary vascular congestion may occur either due to fibrosis of cardiac muscle 
or due to hypertension(27). Myocarditis may be associated with inflammatory muscle 
disease and may be associated with congestive cardiac failure (CCF) or sudden 
cardiac death. Myocarditis in systemic sclerosis has to be differentiated from muscle 
fibrosis in systemic sclerosis. 
           In a study of 100 patients with SSc, Akesson and Wolheim noted that 
cardiomegaly was present in 24% of patients with diffuse scleroderma and in 3 % of 
those with CREST syndrome and an abnormal ECG was present in 35% of the diffuse 
and 25% of limited type (28). 
Follansbee et al compared results of radionuclide evaluation of 22 patients 
with limited scleroderma and 26 patients with diffuse scleroderma. Thallium 
perfusion defects were present in 64% of the limited patients whereas 77% of diffuse 
had defects. In contrast to the diffuse scleroderma patients, thallium perfusion defects 
in the limited scleroderma patients appeared to be functionally not significant. A 
reduced ejection fraction was noted in 36%of patients with limited type. This was due 
to secondary pulmonary hypertension resulting from pulmonary vascular disease in 
patients with limited scleroderma which is rare in diffuse scleroderma (29) 
Kinney E  et al reported that mild valvular abnormalities in the form of 
thickening of the mitral valve, mitral valve prolapse and verrucous endocarditis may 
also be seen in patients with the CREST syndrome(30). Electrocardiographic 
abnormalities and arrhythmias have been reported in both limited and diffuse 
cutaneous types. 
Geirsson et al noted that resting ECG abnormalities were present in 38% with 
limited and 38% of patients with diffuse SSc(31). Using univariate analysis, Kostis et 
al observed that supraventricular and ventricular tachycardia were more frequently 
found in patients with diffuse scleroderma. The extent of skin involvement, however, 
was not a predictor of arrhythmias or mortality in multivariate analysis (32).    
Conduction system disease and arrhythmias may be revealed by ECG and 
Holter monitoring. Premature ventricular contractions are most common arrhythmias. 
Premature atrial contractions, supraventricular tachycardias, atrioventricular or 
intraventricular conduction disturbances are seen less commonly. Arrhythmias are 
quite common in diffuse type. 
PRIMARY PULMONARY HYPERTENSION IN SYSTEMIC SCLEROSIS 
Christopher et al documented a prevalence of 12to 15% of primary 
pulmonary hypertension in a hospital based cohort study. In a retrospective study, 
KOH et al reported 4.9% of pulmonary hypertension. In this study 8 patients had 
primary pulmonary hypertension and 9 patients had secondary pulmonary 
hypertension. Patients with interstitial lung disease developed pulmonary 
hypertension earlier, but had longer survival than patients with primary pulmonary 
hypertension 
Stupi AM et al observed pulmonary hypertension in 9% of patients with 
systemic sclerosis. In 20 of 673 patients primary pulmonary hypertension was 
demonstrated. Chang B et al reported mild to moderate pulmonary hypertension in 
26% of   361 patients and 13.6% of severe pulmonary hypertension. In this study 
patients with mild to moderate pulmonary hypertension had a 17% probability of 
progressing to severe PHT and 15% probability of regressing to no PHT. 
De Azevedo et al documented 28% of PHT in 57 patients of which 8 patients 
had primary pulmonary hypertension and 8 patients had secondary pulmonary 
hypertension.    
PULMONARY HYPERTENSION AND INTERSTITIAL LUNG DISEASE: 
The two major pulmonary problems occurring among SSc patients are 
pulmonary hypertension and interstitial fibrosis. Isolated pulmonary hypertension 
occurs primarily in patients with limited cutaneous SSc in the absence of significant 
pulmonary fibrosis, whereas interstitial fibrosis occurs in either limited or diffuse 
cutaneous SSc. 
PULMONARY VASCULAR DISEASE: 
Pulmonary hypertension may occur as a primary process or secondary to 
interstitial lung disease and is found in 35% to 80% of systemic sclerosis depending 
upon the study population and the method of detection. Clinically detectable severe 
pulmonary hypertension is noted to occur in 9% of systemic sclerosis patients. 
Pulmonary hypertension is defined as resting pulmonary artery pressure greater than 
25mm of Hg or an exercise pulmonary artery pressure (PAP) greater than 30mm of 
Hg. 
Most common physiologic abnormality is a reduced diffusing capacity for 
carbon monoxide (DLCO). An isolated decrease in DLCO (<55%) is associated with 
the development of pulmonary hypertension (PHT) in patients with SSc of limited 
type. Pulmonary vasospasm may be important for the pathogenesis of a diminished 
DLCO  and pulmonary hypertension in SSc. 
Raynaud’s phenomenon occurs in 90% of SSc patients and virtually in all the 
patients with limited type and pulmonary hypertension. Secondary causes of 
pulmonary hypertension include SSc heart disease and interstitial fibrosis.  
Pulmonary hypertension due to parenchymal lung fibrosis may occur in 
patients with either limited or diffuse cutaneous SSc. Interstitial lung disease causes 
compression and obliteration of small pulmonary vessels, resulting in a decrease of 
pulmonary blood volume and vital capacity (VC). The diminished VC and decreased 
pulmonary volume result in an increased pulmonary vasculature resistance and in 
pulmonary hypertension.   
The most common symptom of pulmonary hypertension is dyspnea and one 
third may be asymptomatic. Physical examination might reveal a raise in jugular 
venous pressure, a pulmonary lift, loud pulmonary component of S2 and a right 
ventricular gallop. The anticentromere antibody is specific for limited   cutaneous SSc 
with greater than 95% anticentromere antibody (ACA) positive patients having 
limited cutaneous systemic sclerosis. Only 43% of patients with limited cutaneous 
SSc, however, are ACA positive. Presence of ACA in limited cutaneous systemic 
sclerosis is associated with a decreased likelihood of interstitial lung disease but does 
not predict the likelihood of pulmonary hypertension. 
Sullivan et al in a study demonstrated 73% patients with pulmonary 
hypertension had an abnormal chest radiograph or pulmonary function tests. 
Echocardiogram may show right ventricular enlargement, asymmetric septal 
hypertrophy, paradoxical septal motion or signs of pulmonary hypertension. 
Echocardiography is the most effective non invasive method for detecting moderate to 
severe pulmonary hypertension. 
INTERSTITIAL LUNG DISEASE: 
The prevalence of pulmonary fibrosis in scleroderma varies from 25% to 90% 
depending upon the method used to identify ILD. The restrictive lung disease on 
pulmonary function tests (PFT) is used as the defining abnormality.  
The major clinical feature of SSc interstitial lung disease is a restrictive 
ventilatory defect causing dyspnea on exertion and non productive cough with 
bilateral crackles on auscultation. Pulmonary function tests (PFT) reveal a reduced 
forced vital capacity (FVC) and forced expiratory volume in one second (FEV1); 
residual volume and total lung capacity are reduced. Chest X ray may show linear and 
reticular shadows and in more advanced cases a honey comb appearance. Chest 
radiography is not as sensitive as high resolution computed tomography (HRCT) (33) 
Patchy areas with ground glass appearance correlate with acute cellular 
histopathology, whereas reticular shadows correspond to areas of fibrosis. In chronic 
diffuse infiltrative lung disease, pathologic correlation indicates that areas with 
ground glass attenuation not associated with traction bronchiectasis or 
bronchiolectasis are reliable indicators of inflammation. Ground glass opacification 
correspond to neutrophilic alveolitis by broncho alveolar lavage (BAL) analysis.  
Steen VD et al noted 23% of 88 American patients with limited type 40% of 
77 patients who had diffuse disease had pulmonary fibrosis. 
Owens GR et al predicted pulmonary fibrosis base on chest X ray in 33% 
patients with limited scleroderma and 40% of diffuse type patients(34). 
Steen et al studied 165 nonsmoking patients by PFT and found that restrictive 
lung disease was the most frequent PFT abnormality(35)  
Owens et al reported that 72% of CREST syndrome patients had abnormal 
pulmonary function. (36). 
Harrison et al noted that the earliest to be lymphocytic and plasma cell 
infiltration of alveolar walls, interstitial fibrosis, increased macrophages in the 
alveolar spaces. Inflammatory alveolitis is an initial component of ILD. BAL studies 
have shown neutrophilic alveolitis in 50 to 60% of SSc patients. Increased number of 
eosinophils may also be present in the BAL fluid. The presence of neutrophilic 
alveolitis is associated with worse dyspnea and worse PFT’s and indicate a poor 
prognosis if untreated. BAL fluid analysis reveals lymphocytic predominance in early 
ILD. 
The evolution of ILD involve differentiation of resident fibroblasts to a 
phenotype with increased proliferation and biosynthetic capacities is likely the result 
of the action of a variety of cytokines such as IL1, TNF alpha, IL6, IL8, and 
monocytic chemotactic protein (MCP). Chemotactic factors and chemokines 
produced by alveolar macrophages contribute and lead to perpetuation of fibrosis. 
Platelet Derived Growth Factor (PDGF) and transforming growth factor beta (TGF B) 
are two other essential cytokines in the evolution of interstitial lung disease (ILD). 
PULMONARY HYPERTENSION IN SYSTEMIC SCLEROSIS  
Colgan GT et al noted that pulmonary hypertension is present in 10 to 15% of 
SSc patients (48). Three aspects of PHT need emphasis. Pulmonary hypertension 
complicating limited cutaneous systemic sclerosis is a significant entity. Pulmonary 
hypertension arising from interstitial pulmonary fibrosis and lastly slowly progressive 
PHT in the course of limited cutaneous disease with secondary vascular component 
with mild fibrosis that is distinct fro severe interstitial fibrosis with secondary PHT. 
PATHOGENESIS 
The etiology of pulmonary hypertension in scleroderma spectrum disorders 
remains obscure. There appears to be a direct involvement of pulmonary circulation 
with intimal proliferation and medial hypertrophy similar to that seen in primary 
pulmonary hypertension. Some cases may also be related to severe pulmonary 
parenchymal disease, such as interstitial disease with hypoxemia. 
            Additionally diastolic dysfunctions of right and left ventricles have been seen 
in patients with scleroderma and may contribute to pulmonary hypertension. 
Autoimmune processes have been implicated in the pathogenesis of pulmonary 
hypertension although the mechanism is not known. Positive antinuclear antibodies 
are frequently found in pulmonary hypertension patients without a diagnosis of 
connective tissue disease and pulmonary hypertension can occur before the onset of 
an identifiable connective tissue disease. 
RAYNAUD’S PHENOMENON AND PULMONARY HYPERTENSION 
Raynaud’s phenomenon, vasospasm of arterioles in distal systemic circulation, 
is commonly reported in scleroderma. In one report all patients with PHT and CREST 
syndrome had Raynaud’s while 68% without pulmonary hypertension had Raynaud’s. 
Acute hypoxemic pulmonary vasoconstriction may be more pronounced in patients 
with PHT and SSc than in patients with primary PHT. Another report found that 
pulmonary vasospasm was not present in patients with Raynaud’s and SSc without 
PHT. 
The etiopathogenesis of PHT is complex and multifactorial. Major pathologic 
and histologic similarities exist between Primary pulmonary hypertension (PPHT) and 
systemic sclerosis associated PHT. In systemic sclerosis altered expression of TGF-B 
super family of receptors, interacting proteins or down stream signaling molecules 
occur in SSc. Some studies suggest single nucleotide polymorphisms with SSc . Wide 
spread endothelial cell activation occur in SSc as an earliest lesion. End stage lesion 
of PHT is microvascular luminal obliteration and alteration with medial and 
adventitial fibrosis and proliferative lesions and intimal hyperplasia. Plexiform lesions 
occur more commonly in primary pulmonary hypertension. 
Elevated levels of ET-1 are a feature of PHT associated with systemic 
sclerosis (36). Deficiency in endothelium derived nitric oxide, excessive 
vasoconstrictors like endothelin-1, might contribute to pathogenesis. Less involved 
vessels may be vasodilated. The endothelin receptor blockade is  antifibrotic and 
iloprost seems to down regulate expression of a potentially important, downstream 
proliferative mediator, the connective Tissue Growth Factor (CTGF). 
The earliest symptom could be exertional breathlessness. Chest pain may 
occur due to right ventricular angina and syncope or near syncope due to reduced 
cardiac reserve. Emphasis should be on early diagnosis. PFT’s, Doppler 
echocardiography and ECG aid in the definite diagnosis. Common PFT abnormality is 
reduction in carbon monoxide transfer factor with preservation of lung volumes. 
Isolated and often transient changes in CO diffusing capacity are common in SSc. 
This probably is due to ventilation perfusion alteration resulting in V/Q mismatch. 
Echocardiography plays a vital role in Pulmonary arterial hypertension  
assessment .Structural changes that suggest elevated pulmonary artery pressure 
include increased pulmonary acceleration time, altered movement of inter ventricular 
septum, and impaired right ventricular function of pulmonary outflow dilatation. Peak 
systolic pressure can be assessed by the combination of echocardiography with 
Doppler assignment of regurgitant blood jet velocity through the tricuspid valve. 
Accuracy of the measurement is operator dependent and mild degree of regurgitation 
is hard to assess. With expertise Doppler echocardiography is highly specific and 
sensitive for detecting pulmonary hypertension. Strong correlation exists between 
Doppler estimated peak pulmonary artery pressure and that measured by right heart 
catheterization. 
The prevalence of PAHT is 5 to50% in various published series. The 
relationship between severity and pattern of SSc and pulmonary arterial bypertension 
(PAHT) is unclear. The isolated form is seen in classical limited cutaneous SSc and 
with anticentromere antibody reactivity. It is seen in diffuse cutaneous SSc and is 
associated with antifibrillarin (U3RNP) antibodies. 
Monitoring of all patients with SSc and pulmonary hypertension at least by 
annual doppler echocardiogram and pulmonary function testing is not universally 
accepted as a standard practice. It is essential to have serial measurements of severity 
of pulmonary hypertension. This is accomplished with serial Doppler 
echocardiography, every 5 to 6 months depending upon clinical change, symptom 
severity and exercise capacity. 
The 6 minute walk test has been established as a reproducible simple clinical 
measure of exercise capacity in pulmonary arterial hypertension which often used as 
an end point in clinical trails. It is to be performed regularly in all patients using a 
marked 50 meter course. There are defined levels of encouragement. Patients decide 
when the test is complete unless they exceed 500 meters. 
 OBJECTIVES 
The objectives of the study are: 
1. To study the cardiac manifestations in limited and diffuse cutaneous types of 
systemic sclerosis   
2. To study the pulmonary manifestations including pulmonary hypertension in 
limited and diffuse cutaneous types of systemic sclerosis.  
 
 
MATERIAL AND METHODS 
This study was conducted in the department of Rheumatology, Madras 
Medical College and Govt. General Hospital Chennai during the period between 
August 2004 and  December 2006.All the 63 consecutive patients with systemic 
sclerosis attending the Department of rheumatology, Govt. General Hospital, Chennai 
were included in this study. The patients fulfilling the American College of 
Rheumatology preliminary criteria for the classification of systemic sclerosis were 
included. 
INCLUSION CRITERIA: 
I. Major criteria: 
Sclerodermatous skin change in any location proximal to the 
metacarpophalangeal joints 
II. Minor Criteria: 
1. Sclerodactaly 
2. Digital pitting scars on finger tips or loss of digital finger pad substance 
3. Bibasilar pulmonary fibrosis 
Patients having the major and at least two or more of the minor criteria were 
included in this study. 
The selected cases must be of 16 and above years of age 
 EXCLUSION CRITERIA: 
1. Patients with overlap syndromes were excluded from the study 
2. Patients with features of MCTD and UCTD were excluded. 
3. Patients with previous history of tuberculosis and occupational lung disease 
were excluded 
STUDY DESIGN  
This study was an uncontrolled, prospective study conducted between August 
2004 and December 2006. 63 patients satisfying the inclusion criteria were selected. 
Each patient underwent detailed historical assessment with thorough clinical 
examination. Systemic examination included detailed cardiovascular and pulmonary 
assessment clinically. The extent and severity of skin tightening was recorded with 
modified Rodnan skin scoring system. History, complaints, findings on physical 
examination   was recorded in an investigator administered proforma. The proforma 
was as follows. 
PROFORMA 
Case No: 
Name:                                            Age:                                          Sex: 
I. PRESENTING COMPLAINTS 
1. SKIN TIGHTENING 
a. Diffuse cutaneous                                Yes / No 
b. Limited cutaneous                                Yes / No 
 2. Raynaud’s phenomenon                               Yes / No 
3.  Cardiovascular Features                                
  a. Dyspnea                                             Yes/ No 
 b. Palpitation                                          Yes/ No 
 c. Chest pain                                           Yes/ No 
 d. Syncope                                              Yes/ No 
4. Respiratory System 
 a. Cough                                                  Yes/ No 
 b. Hemoptysis                                         Yes/ No 
 c. Chest pain                                           Yes/ No 
 d. Dyspnea on exertion                           Yes/ No 
 PHYSICAL EXAMINATION 
CVS 
 S1 
 S2                    P2 loud / not loud 
 Added sounds 
RS 
 NVBS 
 Pneumothorax 
 Velcro crackles  
 Features of fibrosis / Atelectasis / Consolidation / Collapse 
INVESTIGATIONS 
ECG 
Echocardiography 
 Left atrial enlargement 
 Right atrial enlargement 
 Pericardial effusion 
 Left ventricular ejection fraction EF% 
 Fractional shortening (FS%) of RV 
 Tricuspid regurgitation / TRPG 
 Transmitral flow velocity 
 Transtricuspid flow velocity 
 Deceleration time 
 Pulmonary artery pressure (PAP) 
 Doppler tissue imaging (mitral annulus / tricuspid annulus) 
 
X-RAY CHEST 
HRCT of Chest 
Pulmonary function tests (Spirometry) 
Broncho alveolar lavage study  
AUTO ANTIBODIES 
 Rheumatoid factor 
 Anti nuclear antibody 
 Scl – 70 anti body 
LIMITATIONS OF THE STUDY 
1. Diffusing capacity for carbon monoxide could not be tested as there is no 
availability 
2. Anticentromere antibody profile could not be done. 
3. 24 hrs continuous ambulatory ECG monitoring could not be accomplished. 
All the eligible patients were subjected for the following investigations: 
X Ray Chest PA view 
Electrocardiogram 
Echocardiogram with Doppler study 
Pulmonary Function Tests (Spirometry) 
Broncho alveolar lavage study (BAL) 
High Resolution Computed Tomography 
Laboratory Tests: 
Rheumatoid Factor by Latex agglutination method 
Antinuclear Antibody (ANA) by Indirect Immunofluorescence 
Scl70 antibody by Elisa method 
X ray Chest: 
Chest X ray standard posteroanterior view was taken and was analyzed for 
features of cardiomegaly (CTR), pulmonary hypertension (Prominent pulmonary 
vasculature and pulmonary main artery (MPA), congestive cardiac Failure (CCF)- 
Kerley B Lines and pericardial effusion. 
Lung fields were divided into 6 radiographic zones and assessment was done 
for the presence of interstitial lung disease (ground glass appearance, reticulonodular 
pattern, pulmonary fibrosis,), bronchiectatic changes, cystic lesions, pleural effusion, 
and pneumothorax. 
ELECTROCARDIOGRAM: 
12 lead standard resting electrocardiogram was recorded in all 63 patients. The 
ECG was analyzed for the following features: 
Right and left atrial enlargement 
Ventricular hypertrophy 
Arrhythmias 
Pericardial effusion 
Ischemic changes, Non specific abnormalities of T wave and ST segment 
ECHOCARDIOGRAPHY 
Echocardiography was done for all the 63 patients by cardiologist. Pulmonary 
arterial pressure was determined.  Doppler recordings were made from the 
parasternal, apical, and subcostal positions using modified views when appropriate. A 
systematic search was performed using two dimensional and color flow Doppler to 
identify the most regurgitant jet followed by continuous wave Doppler acquisition of 
spectral events of greatest maximal velocity and density. A control of 40 patients were 
included and the various measurements were recorded. 
TWO DIMENSIONAL ECHOCARDIOGRAPHY 
Pulmonary hypertension was recognized when the following M mode and 2D 
Echocardiographic features were present 
Diminished or absent “a” (atrial) wave of pulmonary valve 
Midsystolic closure or notching of the pulmonary valve 
Enlarged chambers on the right side of the heart 
D- Shaped left ventricular cavity caused by a flattened ventricular septum 
Pulmonary hypertension is defined as a pulmonary artery systolic pressure 
(PASP) of 25 mm of Hg or more Pulmonary artery pressure control group: For the 
normal population, limited data are available on pulmonary artery pressure estimated 
by Doppler echocardiography. A study of 20 normal healthy adults by Vachiery et al 
using Doppler echocardiography found that the maximum estimated pulmonary artery 
pressure was 24 mm Hg.To assess the diagnostic validity of the results of the 
echocardiogram, a control group of 40 persons were subjected for echocardiogram 
and readings were incorporated into study. 
DEFINITIONS 
Pulmonary hypertension 
The gold standard for pulmonary artery pressure measurement is invasive right 
heart catheterization. Pulmonary hypertension, defined by right heart catheterization 
of the pulmonary artery is a pressure of 25 mm Hg or greater at rest and at least 30 
mm Hg during exercise  Echocardiography has now widely used in patients with 
cardiac disease. Correlations between Doppler and catheter measurements range from 
0.89 to 0.91. The average standard error for systolic pulmonary artery pressure ranges 
from 5 to 9 mm of Hg and inter observer variability is <3%. 
Pulmonary Function Tests: 
Of the total 63 patients 53 patients underwent lung function testing within 1 
week of echocardiographic examination. Pulmonary function testing was performed 
as per the, recommendations of American Thoracic Society. Values are interpreted as 
a percentage of predicted value. 
Significant lung disease: 
Significant lung disease that could be causing pulmonary hypertension was 
defined as pulmonary function measurements outside the normal range: a forced 
expiratory volume in 1 sec/forced vital capacity (FEV1/FVC) ratio of less than 65% 
or a vital lung volume of less than 80% of the predicted value. When PFT was 
abnormal patients were advised to undergo HRCT of lungs to see whether they have 
radiographic evidence of ILD. High resolution CT was performed in all the 63 
Patients (Philips Tomoscan LX:Philips: Eindhoven, the Netherlands).Scans were 
performed at full inspiration in the supine position with 120 KV and 175 mA, 
including continuous scans through the lungs with 10 mm thickness followed by scans 
with 1.5-mm thickness with a slice spacing of 30 mm. 
The patients were identified weather they had ILD or not. If they had features 
of ILD with HRCT with features of pulmonary hypertension they were identified to 
have secondary pulmonary hypertension. Occurrence of pulmonary hypertension 
without associated ILD was known to be due to isolated primary type of pulmonary 
hypertension. 
Broncho Alveolar Lavage 
Fibroptic bronchoscope is wedged in to sub segmental airway, aliquots of 
sterile saline was instilled in to through the scope, allowing sampling of inflammatory 
cells. Recovery of cells enables identification of type of cells and presence of active 
alveolitis, type and chronicity of inflammation in the lower respiratory tract. In the 
study BAL study was performed in 43 cases. Lavage fluid was examined by 
pathologist for the type of inflammatory cells. The differential cell count including 
neutrophils, eosinophils, macrophages, and lymphocytes were analyzed. 
Rheumatoid Factor 
Rheumatoid factor   estimation was done with latex agglutination method. The 
test was considered to be positive if the RF tirer exceeded 1:40 dilution.            
Antinuclear Antibody 
Antinuclear antibody screening was done by Elisa method (Calbiotech INC.). 
ANA screen Elisa test system is an enzyme – linked Immunosorbent assay (ELISA) 
for the detection of IgG class antibodies to ANA in human serum. Antinuclear 
antibodies are frequently present in patients with systemic sclerosis. The ANA 
positivity in scleroderma is up to 97%. ANA Elisa is used as a screening procedure 
for different autoimmune disorders. 
Principle of the test 
Diluted patient serum is added to wells coated with purified nuclear antigens. 
ANA IgG Specific antibody if present, binds to the antigen. All unbound materials are 
washed away and the enzyme conjugate is added to bind to the antibody-antigen 
complex, if present. Excess enzyme conjugate is washed off and the substrate added. 
The plate is incubated to allow the hydrolysis of the substrate by the enzyme. The 
intensity of the color generated is proportional to the amount of   IgG specific 
antibody in the sample. 
Scl-70 autoantibody 
Scl-70 antibody was detected with Elisa (Calibotech INC) .This test system is 
an enzyme linked immunosorbent assay (Elisa) for the detection of IgG class 
antibodies to Scl-70 in human serum or plasma. Scl-70 IgG antibodies react with 
human topoisomerase-I of 100 kd fragment. Scl-70 antibodies are present in 20-40% 
of diffuse scleroderma and in about 20% of patients with limited scleroderma. Scl-70 
antibodies are sometimes reported in classical SLE without features of scleroderma, 
which may explain the unexpected coexistence of marker auto antibodies for SLE and 
Scleroderma. Some patients with silica associated systemic sclerosis have Scl-70 
antibodies. The test is carried out with negative control, positive control, and 
calibrator is used. 
Statistical Analysis : 
 Statistical analysis was done using SPSS Software and the results were 
interpreted. 
 RESULTS 
Sixty three patients who satisfied the American college of rheumatology 
criteria for the classification of systemic sclerosis were subjected to various clinical 
and laboratory investigations including PFT, echocardiography, HRCT, and 
bronchoalveolar lavage study. 
The 63 patients were divided in to 2 groups as to whether they belong to 
diffuse cutaneous or limited cutaneous systemic sclerosis.  
Age, sex and disease duration 
Out of 63 patients there were 5 males and 58 females. The mean age was 37 in 
males and 35 in females 
TABLE: 1 
 No. cases Mean SD t-test 
Male 5 37.20 12.931 
Female 58 35.33 10.088 
t = 0.23 
P = 0.69 
Not significant 
 
The age range was 17 to 60 years. The maximum number of cases occurred in 
the 25 to 40 age group. The female to male ratio was 15:1 (Figure 1). The maximum 
number of cases occurred in the age group of 25 to 40 Years.  
TABLE: 2 Cardiovascular features in diffuse and limited SSc 
Diffuse Limited 
Cardiac features 
n % n % 
Significance 
Positive 13 59.1% 30 73.2%
Raynaud's 
Negative 9 40.9% 11 26.8%
χ2=1.31 
P = 0.25 
Not significant 
Present 5 22.7% 5 12.2%
Palpitation 
Absent 17 77.3% 36 87.8%
χ2 = 1.18 
P = 0.28 
Not significant 
Present 5 22.7% 5 12.2%
Chest Pain 
Absent 17 77.3% 36 87.8%
χ2 = 1.18 
P = 0.28 
Not significant 
Present 7 31.8% 7 17.1%
Dyspnea 
Absent 15 68.2% 34 82.9%
χ2 = 1.80 
P = 0.18 
Not significant 
Yes 2 9.1% 2 4.9% 
Syncope 
No 20 90.9% 39 95.1%
χ2 = 0.43 
P = 0.51 
Not significant 
N 19 86.4% 39 95.1%
BP 
HT 3 13.6% 2 4.9% 
χ2 = 1.50 
P = 0.22 
Not significant 
N 20 90.9% 38 92.7%
JVP 
R 2 9.1% 3 7.3% 
χ2 = 0.06 
P = 0.80 
Not significant 
N 20 90.9% 37 90.2%
P2 
L 2 9.1% 4 9.8% 
χ2 = 0.01 
P = 0.93 
Not significant 
Nor 11 50.0% 27 65.9%
ECG 
Abn 11 50.0% 14 34.1%
χ2 = 1.50 
P = 0.22 
Not significant 
 
An analysis cardiovascular features showed that the Raynaud’s phenomenon 
was noted in 13(59%) (Figure 2) of diffuse type while it was noted in 30(73%) of 
limited cutaneous SSc. palpitation in 5(22%) of diffuse and 5(12%) of limited, chest 
pain 5(22%) of  Diffuse and 5(12%) of limited, dyspnea in 7(31%) of diffuse and 
7(7%) of limited, Hypertension in 3(13%) of diffuse and 2(5%) of limited type. 
TABLE: 3 Cardiovascular features 
The following cardiovascular features were observed in all the cases. The 
percentage of the features is as follows. 
 n % 
Positive 43 68.3% 
Raynaud's 
Negative 20 31.7% 
Present 10 15.9% 
Palpitation 
Absent 53 84.1% 
Present 10 15.9% 
Chest pain 
Absent 53 84.1% 
Present 14 22.2% 
Dyspnea 
Absent 49 77.8% 
Yes 4 6.3% 
Syncope 
No 59 93.7% 
N 58 92.1% 
BP 
HT 5 7.9% 
N 58 92.1% 
JVP 
R 5 7.9% 
N 57 90.5% 
P2 
L 6 9.5% 
Nor 38 60.3% 
ECG 
Abn 25 39.7% 
 
Raynaud’s phenomenon occurred overall in 43 (68.3%) cases (Figure 21). 
Palpitations were present in 10 (15%) of cases. Chest pain was present in 10(15%) of 
cases. Dyspnea was present in about 14 (22%) of cases. Syncope was present 4(6%) 
of cases. Blood pressure was normal in 58(92%) of cases. Hypertension was noted to 
be present in 5(7%) of cases. JVP was normal in 58(92%) of cases and it was raised in 
5(8%) cases. Pulmonary component of the second heart sound was loud in 6(10%) 
cases while it was normal in 57(90%) cases (Figure 3).  
Resting 12 lead ECG showed normal pattern 38 (58%) cases. Low voltage 
QRS complex in 3(4%), intraventricular conduction disturbances in 11% (Figure 15), 
right bundle branch block in 5% (Figure 13), PR prolongation in 4%, left ventricular 
hypertrophy in 3% and left bundle Branch  block in 2% and left anterior fascicular 
block in 1% of cases. 
TABLE 4:   Echocardiographic features 
Valid Frequency Percent 
CMP+PHT 1 1.6 
Mld. PHT 4 6.3 
Mod. PHT 10 15.9 
Mod. PHT  RCMP 1 1.6 
MVP. MR 3 4.8 
Normal  40 63.5 
PHT+TR 1 1.6 
Severe PHT 2 3.2 
Small ASD 1 1.6 
TOTAL 63 100.0 
 
Echocardiographic evaluation was done in all the 63 cases (Figure 4).  
40(64%) cases revealed normal echocardiographic features. Mild PHT was noted in 
4(6%) of cases. Moderate pulmonary hypertension was observed in 10(16%) cases. 
PHT with tricuspid regurgitation was noted in 1 case. Severe PHT was present in 
2(3%) cases (Figure 9). Non of the control subjects had any evidence of pulmonary 
hypertension. Small atrial septal defect (ASD) was seen as a coincidental finding in 1 
case (Figure 11). 
TABLE: 5 Pulmonary features 
No 42 66.7% Cough Yes 21 33.3% 
No 40 63.5% BOE Yes 23 36.5% 
No 55 87.3% Pleu.Pain Yes 8 12.7% 
No 62 98.4% PneumoThorax Yes 1 1.6% 
No 38 60.3% Velcro Yes 25 39.7% 
 
Cough was present in 21(33%) of cases. Breathlessness on exertion was noted 
in 23(36%) of cases. Pleuritic chest pain in 8(13%) , pneumothorax in 1 case. Velcro 
crackles were observed by auscultation in 38(60%) cases. 
TABLE: 6 Pulmonary investigations  
N 39 61.9% 
Mild R 2 3.2% 
MR 12 19.0% 
PFT 
SR 10 15.9% 
Nor 43 68.3% CXR Pos 20 31.7% 
Neg 26 61% BAL Pos 17 39% 
ILD 28 44.4% HRCT Nor 35 55.6% 
 
Pulmonary function testing revealed normal spirometric parameters in 
39(61%) of cases. Mild restriction was noted in 2(3%) cases. Moderate restriction was 
seen in 12(19%) cases. Severe restriction was noted in 10(15%) cases. Chest 
radiography showed  reticulonodular pattern suggestive of  interstitial lung disease in 
20(31%) cases (Figure 10). Broncho alveolar lavage analysis was suggestive of ILD 
in 17(39%) cases (Figure 5). 
HRCT revealed features consistent with ILD in 28(44%) cases (Figures 9 & 
11). 
HRCT findings included ground glass opacity, increased pleural thickening, 
fine reticular pattern, honey combing and mixed reticular and honey compang. Inter 
and intra lobular septal thickening was also noted. HRCT lower lung zone distribution 
was predominant.  
TABLE 6A:  HRCT Findings on HRCT of Chest  
Feature No. of Cases Percentage 
Ground glass opacity  7 25% 
Pleural thickening  4 14% 
Fine reticular pattern 2 7% 
Interlobular thickening  4 14% 
Intralobular thickening  3 11% 
Honey combing  3 11% 
Mixed pattern 3 11% 
Features of extensive fibrosis  2 7% 
 
TABLE: 7 Primary and secondary PHT 
No 56 88.9% PPHT 
Yes 7 11.1% 
No 53 84.1% SPHT 
Yes 10 15.9% 
Neg 45 71.4% RF 
Pos 18 28.6% 
Neg 21 33.3% ANA 
Pos 42 66.7% 
BLP 7 11.1% 
HP 16 25.4% 
MP 12 19.0% 
Scl70 
 
 
Neg 28 44.4% 
 
Primary pulmonary hypertension was noted to be present in 7(11%) cases 
(Figure 6). Secondary Pulmonary hypertension was observed in 10(16%) cases 
(Figure 7). 
TABLE: 8 Secondary PHT in diffuse and limited subtypes 
HRCT 
ILD Nor n Diffuse/Limited 
n % n %  
Significance
No 6 54.5% 11 100.0% 17 D 
 
SPHT 
 Yes 5 45.5%   5 
 Group Total 11 100.0% 11 100.0% 22 
χ2=6.47 
P=0.01 
significant 
No 12 70.6% 24 100.0% 36 L 
 
SPHT 
 Yes 5 29.4%   5 
  Group Total 17 100.0% 24 100.0% 41 
χ2=8.04 
P=0.005 
significant 
 
Secondary PHT due to interstitial lung disease was observed in 5(45%) of total 
of 10 cases in limited cutaneous type. The other 5 cases of secondary pulmonary 
hypertension had diffuse cutaneous type with interstitial lung disease.  
TABLE: 9 X ray and HRCT correlation 
 
Nor 44 85.5% CXR 
  Nor 19 14.5% 
HRCT Nor 35 55.6% 
 Pos 28 44.4% 
Group Total 63 100.0% 
χ2=30.33 
P=0.001 
Significant 
 
Conventional chest skiagraphy showed features consistent with interstitial 
lung disease, in 19(44%) cases while HRCT showed features of ILD in 28(44%) cases 
TABLE: 10 Distribution of pulmonary features 
Diffuse Limited Pulmonary features 
n % n % 
Significance 
No 12 54.5% 30 73.2% Cough 
Yes 10 45.5% 11 26.8% 
χ2=2.23 
P=0.13 
Not significant 
No 12 54.5% 28 68.3% 
BOE 
Yes 10 45.5% 13 31.7% 
χ2=1.17 
P=0.28 
Not significant 
No 19 86.4% 36 87.8% 
Pleu. Pain 
Yes 3 13.6% 5 12.2% 
χ2=0.03 
P=0.87 
Not significant 
No 22 100.0% 40 97.6% Pneumo 
Thorax 
 Yes 0 0% 1 2.4% 
χ2=0.55 
P=0.46 
Not significant 
No 11 50.0% 27 65.9% Velcro 
 Yes 11 50.0% 14 34.1% 
χ2=1.50 
P=0.22 
Not significant 
PFT Mild R 0 0% 2 4.9% 
χ2=2.61 
P=0.46 
Not significant 
 
Cough was seen in 10(45%) in diffuse type and 11(27%) in limited cutaneous 
type. Breathlessness on exertion was seen in 10(45%) in diffuse cutaneous type and 
13(31.7%) in limited type. Pleuritic chest pain in 3(13%) of diffuse and 5(12%) of 
limited type. Pneumothorax was noted in 0% of diffuse and 1 case in limited 
cutaneous type. Velcro crackles were seen in 11(50%) of diffuse and 14(34%) of 
limited type. 
X Ray chest was positive for ILD in 9 out of 22 cases (40%) in diffuse 
cutaneous type and 11 of 41(26%) of limited cutaneous type. X Rays showed 
reticulonodular pattern in all this cases. BAL was positive in13 out of 22(59%)cases 
of diffuse type and 13(31%) of limited type. 
HRCT was consistent with ILD in 11 out of 22 cases of diffuse and 17 of 
41(41%) of Diffuse type. 
TABLE: 12 Secondary PHT and subtypes  
HRCT 
ILD Nor Diffuse/Limited 
n % n % 
n 
Significance
No 6 54.5% 11 100.0% 17 D 
 
SPHT 
 Yes 5 45.5%   5 
 Group Total 11 100.0% 11 100.0% 22 
χ2=6.47 
P=0.01 
significant 
No 12 70.6% 24 100.0% 36 L 
 
SPHT 
 Yes 5 29.4%   5 
 Group Total 17 100.0% 24 100.0% 41 
χ2=8.04 
P=0.005 
significant 
 
Secondary PHT was present in 5 out of 22 diffue and  5 out of 41 limited 
cutaneous types 
TABLE: 13  Scl-70 positivity 
BLP 1 3.6% 6 17.1% 
HP 8 28.6% 8 22.9% 
MP 7 25.0% 5 14.3% 
Scl-70 
Neg 12 42.9% 16 45.7% 
Group Total 28 100.0% 35 100.0% 
χ2=3.75 
P=0.29 
Not significant 
 
Scl 70 positivity was noted as a whole in 35 cases (Figure 8). Border line 
positivity was seen in 1 out of 28 cases in diffuse type, 6 of35 cases of limited type, 
moderate positivity 7 of 28 cases of diffuse and 5 of 35  limited type and high 
positivity in 8 of 28 cases of diffuse and 8 cases of 35 cases of limited cutaneous type. 
TABLE: 14 Rheumatoid factor positivity 
Positive 18 28.6 
Negative 45 71.4 
Total 63 100.0 
 
Out of total cases of 63, 18 (29%) had seropositivity for Rheumatoid factor 
 TABLE:15 ANA auto antibody in SSc 
 Frequency Percent 
Positive 42 66.7 
Negative 21 33.3 
Total 63 100.0 
 
42 (63%) patients have ANA positivity done by indirect immunoflourescence. 
 
 
 
 
DISCUSSION 
Systemic sclerosis occurs predominantly in females. Various studies show the 
female to male ratio to be 3 to 14:1. This study showed a sex ratio of 15:1. Age of 
disease occurrence of systemic sclerosis is in the range of 30-50 years whereas this 
study showed an age range of 17-60 years. The mean age of onset in white men and 
women are 44 and 42. This study showed a mean age of 37 years in males and 35 
years in females. Mean age of onset among African American men and women are 41 
and 38 years. 
 90% of patients with systemic sclerosis have Raynaud’s phenomenon. 68% of 
patients of this study had Raynaud’s phenomenon. Raynaud’s phenomenon occurred 
in 59 % of patients of diffuse type and in 73 % of limited type. Palpitation occurred in 
10 (15.9%) cases. Palpitations occur both in primary and secondary forms of 
pulmonary hypertension. Cardiac involvement can occur in the form of myocardial 
involvement, conduction system abnormalities, arrhythmias or pericardial disease. 
Systemic sclerosis can involve the myocardium, pericardium, and conduction 
sytem of the heart (36). Dyspnea is common, paroxysmal nocturnal dyspnea and 
orthopnea can occur if myocardial involvement is advanced. Pulmonary hypertension 
can present with features of right heart failure. Palpitations either due to brady or 
tachy arrhythmias or just a perceived bounding of the heart beat in sinus rhythm, are 
common. 
Atypical chest pain is common but classical angina and myocardial infarction 
may occur with normal epicardial coronary arteries. Cardiac involvement in SSc is 
clinically occult often and reports of prevalence of cardiac disease vary depending on 
the methods used to identify it. Recent studies suggest that clinical evidence of 
myocardial disease may be seen 20 to 25% of patients with SSc. 
Follansbee et al through autopsy studies have found cardiac involvement 
particularly myocardial fibrosis and pericardial disease are frequent. The prevalence 
of myocardial fibrosis varies between 30-81% in various series. (37) 
Echocardiographic screening of SSc patients has found a high prevalence of 
asymptomatic cardiac abnormalities. 
Smith et al noted that in a study of 54 patients 22(41%) had pericardial 
effusion by echocardiography. Echocardiographic abnormalities have been recorded 
in up to 69% of cases. Patients with palpitations often have atrial or ventricular 
ectopy. If the cardiac involvement becomes clinically manifest, it portends an adverse 
prognosis. 
Medsger and Masi et al predicted clinical cardiac disease in SSc was 
associated with 70% mortality at 5 years (38). Left axis deviation and moderate or 
large pericardial effusion were the two variables to independently predict mortality 
(39). 
As new cardiac technologies evolve many asymptomatic cardiac abnormalities 
may be noted. Long term studies are necessary to determine the outcome and the best 
approach to the treatment of such abnormalities. Diastolic dysfunction has been noted 
to be more common in recent years. Right ventricular diastolic dysfunction seen in 8 
patients and left ventricular diastolic dysfunction occurred in 4 patients. 
When comparing Echo and Doppler differences between patients with SSc and 
controls there was a significant difference between the two groups regarding the right 
ventricular cardiac chamber dimensions. There was a significant difference in the 
estimated pulmonary artery systolic pressure between patients with and without 
ventricular diastolic dysfunction. 
Diastolic dysfunction of RV, LV or both can occur in SSc, which can occur 
with or without the presence of pulmonary hypertension or systemic hypertension. 
More often it is asymptomatic. The extent of the RV diastolic dysfunction was not 
related to the duration of the disease or to the skin score. 
Initial cardiac evaluation at presentation with resting 12 lead ECG in 63 
patients revealed normal pattern 58.7% of cases (37 cases). Low voltage QRS 
complexes were noted in 3 cases (4.8%). Intra ventricular conduction disturbances 
and right bundle branch block were noted in 11.1% and 4.8% (7&3 cases). PR 
prolongation as an isolated abnormality was seen 4.8% (3) cases. Left ventricular 
hypertrophy was seen in 2 cases. Left bundle branch block and left anterior fasicular 
block were seen in 1 case each. 
Follansbee WP et al in their review of 436 patients have noted the prevalence 
of abnormalities of on resting ECG which revealed normal ECG in 56%, PR 
prolongation in 5%, RBBB in 2%, LBBB in 1%, LAFB in 5%, intraventricular 
conduction disturbances in 4%, LVH in 7% and non specific ST –T wave 
abnormalities in7% and low voltage QRS in 5% of cases. 
Patchy myocardial fibrosis and conduction system disease in SSc patients 
form a substrate for the generation of supraventricular and ventricular arrhythmias 
(40). Cardiac involvement in SSc is often clinically occult and hence reports of the 
prevalence of cardiac disease vary depending upon methods used to define this entity. 
It is increasingly recognized that significant pulmonary arterial hypertension in more 
than 15% of patients with SSc. As this complication can occur even in the absence of 
overt interstitial lung disease (Isolated PAH), it has been linked to primary PAH and 
is attributable to intrinsic vascular pathology that is the hallmark of SSc.  
Deregulatory activity of mediators controlling vasomotor tone has been 
implicated, and the level of endothelin-1 (ET-!) are elevated in the circulation and in 
the lung. Enhanced vasoconstriction, vascular endothelial proliferation, smooth 
muscle hypertrophy and irreversible vascular remodeling in lung, ET-1 appears to 
play a role in pathogenesis. 
SSc is often associated with pulmonary hypertension. Although patients with 
limited cutaneous type are more likely to develop PHT than those with diffuse form of 
SSc, the true prevalence of PHT in SSc and the risk factors associated with its 
development are unknown .Primary pulmonary hypertension occurred in 7(11%)  of 
cases and secondary PHT in 10 (15.9) cases. Because the prognosis of patients with 
SSc associated with PHT is substantially worse than that of patients without this 
complication, intensive efforts are underway to develop sensitive screening strategies 
and effective treatment. Serial evaluation of SSc patients with Doppler 
echocardiography appears to be prudent (41). Most studies differentiate scleroderma 
associated PHT and ILD as a two separate pathologies concentrating on one or the 
other; however, many patients have both problems. 
Chang et al in a retrospective cross sectional study of 614 patients with SSc 
who had echocardiography and PFT performed within 6 months of one another. 
Echocardiography determined presence of pulmonary hypertension and PFT 
documented Restrictive ventilatory defect (RVD). 22.5% had isolated RVD; 19.2% 
had isolated PHT; 18.1% had both combined RVD and isolated PHT. The individuals 
with combined RVD and PHT resembled patients with isolated RVD in that they had 
a high prevalence of diffuse skin involvement and antitopoisomerase positivity. 
39.2% patients with  mild RVD and 51.4% of  severe RVD had pulmonary 
hypertension(42). 
De Azevedo AB et al have noted a prevalence of 28%  in a study of 16 
patients(43). 
Chang et al used a cohort of 1136 SSc patients predicted the risk factor for 
pulmonary hypertension which include older age, limited skin disease, and elevated 
pulmonary artery pressures at the time of initial evaluation (44) 
In another study Stupi et al assessed the occurrence of pulmonary 
hypertension in CREST syndrome. They reported 59 of 673 CREST syndrome 
patients had PHT. 
Koh ET et al analyzed retrospectively 344 patients with SSc followed 
prospectively for the occurrence of PHT.  17 (4.9%) were found to have PHT. 8 had 
isolated PHT while 9 had PHT secondary to ILD. Patients with RVD developed PHT 
earlier but the survival was better that of PHT. 
A patient with limited cutaneous SSc presented with acute breathlessness with 
congestive cardiac failure and she was found to have biventricular dysfunction with 
dilated cardiomyopathy and moderate pulmonary hypertension. There was complete 
recovery with reversal of PHT and biventricular function normalized after 3 months. 
This illustrates the occurrence reversible cardiomyopathy due to disturbances of 
microcirculation of the heart vessels, probably due to systemic Raynaud’s 
phenomenon. This might have resulted in transient, persistent microcirculatory 
disturbances causing ventricular dysfunction and cardiomyopathy.  
The literature pertaining to the interstitial lung disease indicates that it is a 
major contributor of morbidity and mortality. The clinical approach to staging of the 
disease activity remains controversial. High resolution computed tomographic scans, 
broncho alveolar lavage, and various serum markers (e.g., surfactant protein D and 
KL-6) each may provide useful information about the degree of activity of the 
systemic sclerosis- interstitial lung disease.(45). Abnormalities of lung function occur 
in 70% of patients with systemic sclerosis. Screening of patients recently diagnosed 
with SSc by pulmonary function tests and HRCT identify a significant number of 
patients with early asymptomatic fibrosing alvoelitis in systemic sclerosis 
(FASSc)(46).  
Interstitial lung disease associated with SSc is seen in diffuse disease, though 
it can be present in limited disease also. The nonspecific nature of SSc associated ILD 
makes it different from idiopathic ILD and helps to explain its better prognosis. ILD 
is one of the leading two causes of death in SSc. (47). 
Dyspnea in scleroderma patients can be due to chest wall tightening and skin 
involvement, pleural disease, cardiac involvement, myositis of intercostals muscles, 
or due to scleroderma lung disease. Scleroderma lung disease encompasses vascular 
(PHT) or ILD or both. A comprehensive work up is required to delineate the 
underlying cause of dyspnea in a scleroderma patient, and to establish the contribution 
of each component to symptoms. (48). Pulmonary function tests play a vital role in 
the evaluation of Patients with systemic sclerosis and for assessing the presence and 
the severity of SSc lung involvement. But they have got limitations as patients with 
severe skin disease might encounter problems in performing the tests. However they 
play a crucial role in the evaluation of lung function in the early disease.  X ray of the 
chest is least sensitive in indicating the lung abnormalities but it does have role in the 
assessment of severe disease.   
The incidence of radio graphically recognizable interstitial lung disease is 
around 25%. The range varies from 10 to 80%. Usual interstitial pneumonia, is 
common form of ILD. But occasionally non-specific interstitial pneumonia (NSIP) 
also occurs. The HRCT findings of interstitial lung disease in SSc are honey combing, 
irregular reticulation, sub pleural lines, ground glass opacity, consolidation, and a 
subpleural distribution. 
Chan et al compared the HRCT findings of 52 patients with idiopathic 
pulmonary fibrosis with 52 patients of SSc with ILD. He concluded that the patients 
with SSc have fine reticular pattern and less upper Zone involvement. 
Schurawitzki et al studied 23 patients with SSc. HRCT findings include 
subpleural lines (74%), septal thickening or parenchymal bands(43%) and 
honeycombing(43%). Honeycombing had uniform or peripheral distribution. 
Parenchymal abnormalities had upper lung to middle lung to lower lung distribution 
ratios of 1:2.4:3.8, conforming the typical lower lung zone predominance or 
abnormalities. 
Remy-jardin et al reviewed the HRCT, PFT and BAL results of 53 patients 
with SSc emphasizing the frequency of honey combing and ground glass opacity. 
These abnormalities have a basal, posterior and peripheral predominance. Small 
nodules with or without honeycombing is reported. HRCT ground glass opacity 
indicates reduction in diffusing capacity while honeycombing indicates reduction in 
lung volumes and diffusing capacity. Increased pleural thickening, esophageal 
dilatation, in 40 to 60% of patients. 
Predominant ground glass appearance correlates with alveolitis and reticular 
pattern correlate with presence of fibrosis in pathogenic specimens. Out of  28(44%) 
patients who had ILD by HRCT   12 had ground glass opacities, 8 had fine reticular 
pattern 4 had features of  honey combing and 4 had mixed findings of  reticular and  
extensive honeycombing.  In this study BAL identified ILD in 41% of patients 
whereas HRCT could identify 44% of patients with interstitial lung disease. 
  
 
 
CONCLUSION 
1. Systemic sclerosis is common in females and the female: male ratio is 15:1, 
with an age range of 17 to 60 years with a mean age of 37 in males and 35 in 
females. 
2. Limited cutaneous type of presentation is more common.  
3. Raynaud’s phenomenon is seen in both limited and diffuse cutaneous types, 
but the occurrence is more common in limited cutaneous type. 
4. Secondary pulmonary hypertension due to interstitial lung is more common 
than the primary type of pulmonary hypertension. 
5. Resting ECG revealed abnormalities in 42% of patients. ST-T wave changes 
followed by intra ventricular conduction disturbances constitute the most 
common abnormalities. 
6. Mild pulmonary hypertension was noted in 6.3%, modereate pulmonary 
hypertension in 15.9%, and severe PHT in 3.2% of patients. Reversible 
cardiomyopathy was seen in 1 patient. 
7. Mitral valve prolapse with or without mitral regurgitation was observed in 
4.8% of patients. 
8. Significant difference was noted in the right and left ventricular chamber 
dimensions between the patients and normal controls. The difference in the 
estimated pulmonary pressure was considerable in patients with and without 
ventricular diastolic dysfunction. 
 
 9. Chest X ray showed features of interstitial lung disease in 31.7% while HRCT             
revealed features of interstitial lung disease in 44.4% of individuals. 
10. Pulmonary function tests showed mild restrictive type of ventilatory defect in 
3.2%, moderate restriction in 19% and severe restriction in 15.9%. Normal 
PFT was seen in 61.9% of patients. 
11. Interstitial lung disease was more common in diffuse cutaneous systemic 
sclerosis. 
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APPENDIX - II 
ABBREVIATION CODE FOR MASTER CHART 
BP  - Blood pressure 
JVP  - Jugular venous pressure 
P2  - Pulmonary component of second heart sound 
ECG  - Electrocardiogram 
Echo  - Echocardiography 
BOE  - Breathlessness on exertion 
Pleu.Pain - Pleutitic chest pain 
Velcro  - Velcro Crackles 
PFT  - Pulmonary function tests 
CXR  - X ray chest PA view 
BAL  - Bronchoalveolar lavage 
HRCT  - High resolution computed tomography 
PPHT  - Primary pulmonary hypertension 
SPHT  - Secondary pulmonary hypertension 
RF  - Rheumatoid factor 
ANA  - Antinuclear antibody 
Scl-70  - Anti Scl-70 auto antibody   
  
 
 
 
 
 
 
Figure 9 : Apical-4 chamber view shows features of Dilated 
 Cardiomyopathy LA & LV dilated/MR(moderate) 
 
 
 
 
 
 
 
 
 
Figure  10:  TDI of DCMP showing reduced septal annular motion velocity 
  
 
 
 
 
 
 
Figure 11 : M-Mode Echo of DCMP 
 
 
 
 
 
 
 
 
 
 
Figure  12:  Echo shows continuous wave Doppler across the tricuspid valve 
indicating moderate PHT/ continuous wave Doppler across the pulmonary valve 
indicating moderate pulmonary regurgitation due to PHT 
  
 
 
 
 
 
 
Figure  13 : 12 lead ECG showing Complete RBBB 
  
 
 
 
 
 
 
 
 
 Figure  14: 12 lead ECG showing Features of Right ventricular  
   hypertrophy 
   
 
 
 
 
 
 
 Figure  15: 12 lead ECG showing Features of Intraventricular  
   conduction defect 
 
 
Picture  16 :  Picture showing diffuse cutaneous systemic sclerosis with chest 
  involvement 
  
 
 
 
 
 
 
 
Figure  17  : HRCT showing inter ,intra lobular septal thickening and nodular 
  opacities pattern in both lower lobes, more on the right side 
 
 
 
 
 
 
 
 
Figure 18 :  X-ray chest showing bilateral reticulonodular pattern 
  
 
 
 
 
 
 
Figure 19 : HRCT lungs showing bilateral reticulonodular shadows and fibrosis 
 
 
 
 
 
 
 
Figure 20 :  Picture showing pursing of lips and characteristic facies of 
scleroderma 
  
 
 
 
 
 
 
 
 
Figure 21 : Picture showing Raynaud’s phenomenon 
 
 
 
 
 
 
 
 
Figure 22 : Picture showing contracture and deformities of both hands.               
  Shortening of fingers with pigmentary changes and healed ulcers 
  over the  MCP and PIP joints 
                   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23 : Picture showing sclerodactyly 
 
 
 
 
 
 
  
 
S.No Age Sex Diffuse/ Limited Raynauds Palpitation chest Pain Dyspnea
Syn 
cope BP JVP P2 ECG Echo Cough BOE
Pleu. 
Pain
Pneumo 
Thorax Velcro PFT CXR BAL HRCT PPHT SPHT RF ANA
1 22 F D Positive Present Present Present No N R N Abn CMP+PHT Yes Yes No No No N Nor Neg Nor No No Neg Pos
2 48 F L Negative Absent Absent Absent No N N N Nor N No No No No No SR Nor Neg Nor No No Pos Pos
3 55 F D Positive Absent Absent Absent No N N N Abn PHT+TR No No No No No SR Nor Neg Nor No No Neg Neg
4 31 F L Positive Absent Absent Absent No N N N Abn N No No No No No MR Pos Neg ILD No No Neg Neg
5 39 F L Positive Absent Absent Absent No N N N Nor N No No No No Yes MR Pos Pos ILD No No Neg Pos
6 40 F D Positive Absent Present Absent No N N N Abn N No No No No Yes MR Pos Pos ILD No No Pos Pos
7 40 F L Positive Absent Absent Present No N N N Nor N Yes Yes Yes No Yes Mild R Pos Pos ILD No No Neg Pos
8 42 M D Negative Absent Absent Absent No N N N Nor N No No No No Yes N Pos Pos ILD No No Neg Pos
9 33 F D Positive Absent Absent Present No N N N Abn N Yes Yes Yes No Yes MR Neg Pos Nor No No Neg Neg
10 20 F L Negative Absent Absent Absent No N N N Nor N No Yes No No Yes N Neg Neg Nor Yes No Pos Neg
11 29 F L Positive Absent Absent Absent Yes HT N N Abn Mod. PHT +RCMP Yes Yes Yes No No N Pos Neg ILD No No Pos Pos
12 30 F L Negative Absent Absent Absent No N N N Nor Small ASD No No No No Yes N Pos Pos ILD No Yes Neg Pos
13 32 F L Negative Absent Absent Absent No N N N Nor Mod. PHT No No No No Yes N Pos Pos ILD No Yes Neg Pos
14 33 M D Negative Present Present Present No N N N Nor Mod. PHT Yes Yes No No No SR Neg Pos Nor No No Neg Pos
15 50 M D Positive Absent Absent Absent No N N N Nor N Yes Yes No No No N Nor Neg Nor Yes No Pos Pos
16 45 F D Positive Present Present Present Yes N R L Nor Mod. PHT Yes Yes No No No N Pos Neg Nor Yes No Neg Pos
17 20 F L Positive Present Present Present No N R L Nor Severe PHT Yes Yes No No No N Nor Neg ILD No No Neg Pos
18 30 F L Positive Absent Absent Absent No N N N Nor N Yes Yes No No No MR Nor Pos Nor No No Neg Neg
19 29 F D Positive Absent Absent Present No N N N Nor N No Yes No No No N Nor Neg Nor No No Pos Neg
20 42 M D Positive Absent Absent Absent No N N N Nor N No No No No Yes MR Pos Pos ILD No No Neg Pos
21 30 F L Negative Absent Absent Present No N N N Nor Mod. PHT No No No No No N Nor Neg Nor Yes No Neg Neg
22 32 F L Negative Absent Absent Absent No N N N Abn N No No No No No N Nor Neg Nor No No Neg Neg
23 40 F D Positive Absent Absent Absent No N N N Nor N No No No No Yes N Nor Pos ILD No No Neg Pos
24 45 F L Positive Absent Absent Absent No N N N Abn N No No No No Yes N Nor Neg ILD No No Pos Pos
25 48 F L Negative Absent Absent Absent No N N N Nor N No No No No No N Nor Neg Nor No No Neg Pos
26 40 F L Negative Present Present Present No N N L Abn Mod. PHT No No No No Yes MR Nor Pos ILD No Yes Neg Neg
27 33 F D Positive Present Present Present Yes N N L Abn Mod. PHT No No No No Yes MR Pos Pos ILD No Yes Neg Pos
28 33 F D Negative Present Absent Present No N N N Nor N No No No No Yes N Nor Pos ILD No Yes Pos Neg
29 28 F L Positive Absent Absent Absent No N N N Nor Mld. PHT No No No No No SR Nor Neg Nor No No Neg Neg
30 29 F L Positive Absent Absent Absent No N N N Nor N No No No No No N Nor Neg Nor No No Neg Pos
31 36 F L Negative Absent Absent Absent No N N N Nor N Yes Yes No No Yes N Nor Pos ILD No No Neg Pos
APPENDIX - I
CARDIOVASCULAR FEATURES RESPIRATORY FEATURES AUTO ANTIB
MASTER CHART
S.No Age Sex Diffuse/ Limited Raynauds Palpitation chest Pain Dyspnea
Syn 
cope BP JVP P2 ECG Echo Cough BOE
Pleu. 
Pain
Pneumo 
Thorax Velcro PFT CXR BAL HRCT PPHT SPHT RF ANA
CARDIOVASCULAR FEATURES RESPIRATORY FEATURES AUTO ANTIB
32 24 F L Negative Absent Absent Absent No N N N Nor MVP. MR Yes Yes No No Yes SR Nor Pos ILD No No Pos Pos
33 35 F D Negative Absent Absent Absent No HT N N Nor Mld. PHT Yes Yes No No Yes MR Pos Pos ILD No Yes Neg Neg
34 23 F D Negative Absent Absent Absent No HT N N Nor N No No No No No N Nor Neg Nor No No Neg Neg
35 48 F L Positive Absent Absent Absent No N N N Nor N No No No No No N Nor Neg Nor No No Pos Pos
36 23 F L Positive Absent Absent Absent No N R L Abn Mod. PHT Yes Yes Yes No Yes MR Pos Pos ILD No Yes Neg Pos
37 28 F L Positive Present Present Present Yes N R L Abn Mod. PHT Yes Yes No No Yes MR Pos Pos ILD No Yes Pos Pos
38 32 M L Positive Absent Absent Absent No N N N Nor N No No No No No N Nor Neg Nor No No Neg Neg
39 46 F L Positive Absent Absent Absent No N N N Abn N No No No No No N Nor Neg Nor No No Pos Neg
40 25 F L Positive Absent Absent Absent No N N N Nor N No No No No No N Nor Neg Nor No No Neg Pos
41 17 F L Positive Absent Absent Absent No N N N Abn N No No Yes No No N Nor Neg Nor No No Neg Pos
42 54 F L Positive Present Absent Present No N N N Abn Mod. PHT No No No No No N Nor Neg Nor Yes No Neg Pos
43 32 F L Positive Absent Absent Absent No N N N Nor Mld. PHT No No No No No N Nor Neg Nor Yes No Pos Neg
44 47 F L Positive Absent Absent Absent No N N N Abn N No No No No No N Nor Neg Nor No No Neg Pos
45 36 F L Positive Absent Absent Absent No N N N Nor MVP. MR Yes Yes No No Yes MR Pos Pos ILD No No Neg Pos
46 55 F D Negative Absent Absent Absent No N N N Nor MVP. MR Yes No No No Yes N Nor Pos ILD No No Neg Neg
47 35 F D Positive Absent Absent Absent No N N N Abn N No No No No No N Nor Neg Nor No No Neg Neg
48 37 F L Positive Present Present Present No N N N Nor Mld. PHT No No No No Yes N Nor Neg Nor Yes No Neg Neg
49 39 F L Positive Absent Absent Absent No N N N Abn N Yes Yes No No Yes SR Pos Pos ILD No No Neg Pos
50 37 F L Positive Absent Absent Absent No N N N Nor N No No No No No N Nor Neg Nor No No Pos Pos
51 17 F L Positive Absent Absent Absent No N N N Nor N No No No No No N Nor Neg Nor No No Neg Pos
52 40 F D Negative Absent Absent Absent No N N N Abn Severe PHT Yes Yes Yes No Yes SR Pos Pos ILD No Yes Neg Pos
53 24 F L Positive Absent Present Absent No N N N Nor N Yes Yes Yes Yes No SR Pos Neg ILD No No Pos Pos
54 28 F L Positive Absent Absent Absent No N N N Nor N No Yes No No No Mild R Nor Neg ILD No No Neg Pos
55 38 F L Negative Absent Absent Absent No N N N Abn N No No No No No N Nor Neg Nor No No Pos Neg
56 38 F L Positive Absent Absent Absent No HT N N Abn N No No No No No N Nor Neg Nor No No Neg Pos
57 24 F L Positive Absent Absent Absent No N N N Nor N No No No No No N Nor Neg Nor No No Neg Pos
58 60 F D Positive Absent Absent Absent No HT N N Abn N No No No No No N Nor Neg Nor No No Pos Pos
59 31 F L Positive Absent Absent Absent No N N N Nor N No No No No No N Nor Pos Nor No No Neg Neg
60 55 F D Negative Absent Absent Absent No N N N Abn N No No No No No N Nor Neg Nor No No Neg Pos
61 43 F D Positive Absent Absent Absent No N N N Abn N Yes Yes Yes No Yes SR Pos Pos ILD No No Pos Pos
62 42 F D Negative Absent Absent Absent No N N N Abn Mod. PHT Yes Yes No No No SR Pos Pos ILD No Yes Neg Pos
63 18 F L Positive Absent Absent Absent No N N N Nor N No No No No No N Nor Neg Nor No No Neg Pos
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Figure 7 : SPHT
